February 24, 2022 14:00 UTC
New Frontiers in the RWD and Current Use-Cases for RWD Collection
Powered by AMS and Glatt Pharmaceutical Services
Fewer than half of new drugs have data on their comparative benefits and harms against existing treatment options at the time of regulatory approval in Europe and the USA. Comparative evidence generation is even sparser for medical devices. Use of non-randomised studies for the evaluation of clinical benefit in the post-marketing period …
Feb 24, 2022 03:00 PM in Amsterdam, Berlin, Rome, Stockholm, Vienna
Read More